Advaxis, Inc. (NASDAQ:ADXS) major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the firm’s stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Adage Capital Partners Gp, L.L also recently made the following trade(s):
- On Tuesday, September 26th, Adage Capital Partners Gp, L.L sold 1,239,323 shares of Advaxis stock. The shares were sold at an average price of $4.42, for a total transaction of $5,477,807.66.
Shares of Advaxis, Inc. (NASDAQ:ADXS) traded down 2.42% during midday trading on Friday, reaching $4.04. 483,883 shares of the company traded hands. The company has a 50-day moving average of $5.31 and a 200 day moving average of $6.85. The firm’s market capitalization is $165.90 million. Advaxis, Inc. has a 12-month low of $3.90 and a 12-month high of $11.14.
Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). The company had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. On average, equities analysts forecast that Advaxis, Inc. will post ($2.23) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://sportsperspectives.com/2017/10/13/advaxis-inc-adxs-major-shareholder-adage-capital-partners-gp-l-l-sells-600000-shares-of-stock.html.
ADXS has been the subject of several recent analyst reports. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the company a “buy” rating in a research note on Thursday, July 6th. BidaskClub upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research note on Saturday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Advaxis in a research note on Friday, September 15th. Finally, ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Advaxis by 9.2% in the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock valued at $13,587,000 after acquiring an additional 139,710 shares during the last quarter. Teachers Advisors LLC boosted its stake in Advaxis by 4.8% in the fourth quarter. Teachers Advisors LLC now owns 63,296 shares of the biotechnology company’s stock valued at $453,000 after acquiring an additional 2,902 shares during the last quarter. Geode Capital Management LLC boosted its stake in Advaxis by 4.8% in the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock valued at $2,286,000 after acquiring an additional 12,736 shares during the last quarter. Swiss National Bank boosted its stake in Advaxis by 17.5% in the first quarter. Swiss National Bank now owns 55,800 shares of the biotechnology company’s stock valued at $456,000 after acquiring an additional 8,300 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd purchased a new position in Advaxis in the first quarter valued at about $2,455,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.